Product Name :
Oxamflatin
Description:
Oxamflatin (Metacept-3) is a potent HDAC inhibitor with an IC50 of 15.7 nM.
CAS:
151720-43-3
Molecular Weight:
342.37
Formula:
C17H14N2O4S
Chemical Name:
N-hydroxy(Z,2E)-5-(3-benzenesulfonamidophenyl)pent-2-en-4-ynimidic acid
Smiles :
O/C(/C=C/C#CC1=CC(=CC=C1)NS(=O)(=O)C1C=CC=CC=1)=N\O
InChiKey:
QRPSQQUYPMFERG-LFYBBSHMSA-N
InChi :
InChI=1S/C17H14N2O4S/c20-17(18-21)12-5-4-7-14-8-6-9-15(13-14)19-24(22,23)16-10-2-1-3-11-16/h1-3,5-6,8-13,19,21H,(H,18,20)/b12-5+
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Oxamflatin (Metacept-3) is a potent HDAC inhibitor with an IC50 of 15.7 nM.|Product information|CAS Number: 151720-43-3|Molecular Weight: 342.37|Formula: C17H14N2O4S|Chemical Name: N-hydroxy(Z,2E)-5-(3-benzenesulfonamidophenyl)pent-2-en-4-ynimidic acid|Smiles: O/C(/C=C/C#CC1=CC(=CC=C1)NS(=O)(=O)C1C=CC=CC=1)=N\O|InChiKey: QRPSQQUYPMFERG-LFYBBSHMSA-N|InChi: InChI=1S/C17H14N2O4S/c20-17(18-21)12-5-4-7-14-8-6-9-15(13-14)19-24(22,23)16-10-2-1-3-11-16/h1-3,5-6,8-13,19,21H,(H,18,20)/b12-5+|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 50 mg/mL (146.04 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Oxamflatin induces transcriptional activation of junD and morphological reversion in various NIH3T3-derived transformed cell lines. Oxamflatin shows antiproliferative activity against various mouse and human tumor cell lines with drastic changes in the cell morphology. Oxamflatin causes an elongated cell shape with filamentous protrusions as well as arrest of the cell cycle at the G1 phase in HeLa cells.Fludarabine Protocol Oxamflatin greatly enhances the transcriptional activity of the CMV promoter in a dose-dependent manner and inhibits intracellular HDAC activity.GSK1059615 Technical Information Oxamflatin in the nanomolar range induces morphological changes in OVCAR-5 and SKOV-3 ovarian cancer cell lines.PMID:32711871 Treatment with oxamflatin also leads to decreased cell viability. Oxamflatin is able to significantly inhibit DNA synthesis and cell proliferation. Oxamflatin can induce E-cadherin expression and also reduce cell viability in the MKN-45 cell line.|In Vivo:|Injection of oxamflatin, six times at the dose of 20 mg/kg, exhibits a significant increase in the days of survival (38% of ILS). The ILS of the mice treated with oxamflatin at the dose of 50 mg/kg is calculated to be more than 67% and one mouse survived over 60 days after tumor inoculation. No subsidiary effect, such as body weight loss, is observed at least up to this dose.|Products are for research use only. Not for human use.|